Evotec has entered a strategic R&D collaboration with Odyssey Therapeutics to discover potential new treatments in autoimmune and inflammatory diseases. 

Under the agreement, Odyssey will use Evotec’s data-driven discovery platform, screening capabilities and AI-enabled data science technologies to discover and validate differentiated small molecule drug candidates across multiple high-value disease targets.  

The collaboration is designed to accelerate the identification of validated hit series and enable the rapid progression of promising therapeutic programmes with the potential to transform the standard of care. 

The collaboration combines Odyssey’s deep expertise in autoimmune and inflammatory disease biology with Evotec’s discovery infrastructure and proprietary compound libraries. By bringing together complementary scientific and technological strengths, the companies aim to accelerate early-stage research and efficiently generate and advance new medicines. 

Dr Cord Dohrmann, Chief Scientific Officer of Evotec, said: “Drug discovery increasingly depends on the ability to integrate deep disease biology with advanced experimental and computational approaches to drug discovery. This collaboration with Odyssey illustrates well Evotec’s strategy in applying integrated discovery platform technologies to complex disease areas where new approaches are urgently needed. Together, we aim to generate differentiated and validated starting points for Odyssey to develop into new therapies for autoimmune and inflammatory diseases.” 

Evotec is eligible to receive milestone payments based on the successful delivery of validated hit series for each target, though financial details have not been disclosed.